【摘要】 目的　提高人脑胶质瘤过继免疫治疗的效果 ,探索治疗脑胶质瘤的新途径。方法　用植物血凝素 (PHA)、抗CD3单抗 (CD3)和IL 2共同诱导人外周血单个核细胞 (PBMC) ,诱导、扩增新型抗胶质瘤效应细胞PHA CD3AK细胞 ,并与CD3AK细胞在某些生物学方面进行了比较。结果　两组效应细胞增殖曲线均于第 6天达高峰 ,峰值可见 ,PHA CD3AK细胞 >CD3AK (P <0 0 5 ) ;PHA CD3AK细胞扩增倍数明显高于CD3AK细胞 (P <0 0 5 ) ;两组效应细胞于培养的第 6、 8、 10天所测得的杀伤胶质瘤细胞BT32 5活性可见 ,PHA CD3AK细胞 >CD3AK细胞 (P <0 0 5 )。结论　PHA、CD3和IL 2具有协同增强作用 ,使PHA CD3AK细胞成为较CD3AK细胞增殖能力、杀伤活性更强的免疫效应细胞 ,且IL 2用量减少 ,为胶质瘤的过继免疫治疗打下了理论基础更多还原

【Abstract】 Objective To investigate a new clinical therapeutic approach for adoptive immunotherapy as malignant gliomas. Methods In this study, a new type of killer cells, named PHA CD3AK cells was induced by means of costimulating peripheral blood mononuclear cells with phytohemagglutinim (PHA), anti CD3 monoclonal antibody (CD3) and Interleukin 2(IL 2), Its biological characteristics were compared with the control group, named CD3AK cells, induced by means of stimulating PBMC with CD3 and IL 2.Results Both PHA CD3AK cells and CD3AK cells, performed the highest proliferation during the 6th day of culture. It is obvious that the amount of proliferation of PHA CD3 cells is higher than that of CD3AK cells P<0 05). The actual multiplication fold of the former is much more than that of the control group. Moreover, PHA CD3AK cells gained an advantage over the control group in cytotoxicity against malignant glioma cells (BT325) during the 6th, 7th and 8th day of cuture (P<0 05). Conclusions As a new type of killer cells, PHA CD3AK cells have some advantages over the control group CD3AK cells in proliferation, cytotoxicity against BT325, and the utilizing amount of IL 2, indicating the synergistic enhancing role of PHA, CD3 and IL 2. The application of PHA CD3AK cells might open a new prospect to clinical therapeutic approach for maligant gliomas.更多还原